Institutional members access full text with Ovid®

Share this article on:

The Emerging Role of Adipocytokines as Inflammatory Mediators in Inflammatory Bowel Disease

Karmiris, Konstantinos MD1; Koutroubakis, Ioannis E MD1,*; Kouroumalis, Elias A MD, PhD1

doi: 10.1097/01.mib.0000178915.54264.8f
Basic Science Review

Anorexia, malnutrition, altered body composition and development of mesenteric obesity are well known features of inflammatory bowel disease (IBD). Recent data suggest that dysregulation of protein secretion by white adipose tissue is involved in these manifestations of patients with IBD. Adipocytes are recently recognized as endocrine cells that secrete a variety of bioactive substances known as adipocytokines. There is evidence that adipocytokines are involved in inflammatory and metabolic pathways in human beings. Overexpression of adipocytokines such as leptin, adiponectin and resistin in mesenteric adipose tissue of operated patients with Crohn's disease has recently been reported, suggesting that mesenteric adipocytes in IBD may act as immunoregulating cells. Therefore, it could be suggested that adipocytokines play an important role in the disease pathogenesis. Moreover, modulators of mesenteric adipose function have been suggested as potential therapeutic drugs in IBD. In this review, the importance of white adipose tissue function and adipocytokines, is discussed with respect to IBD.

1Department of Gastroenterology, University Hospital of Heraklion, Crete, Greece

*Reprints: Department of Gastroenterology, University Hospital Heraklion, PO Box 1352, 71110 Heraklion, Crete, Greece (e-mail:

Received for publication 18 June 2005; accepted 24 June 2005

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website